Using forensic autopsy data to estimate the age-specific infection fatality risk of COVID-19 Authors: Yuri Amemiya, Hiroshi Nishiura Published: 2026 ABSTRACT The infection fatality risk indicates the probability of death among infected individuals. The age-dependent heterogeneity of infection fatality risk is crucial for severity assessment and prioritization of countermeasures. However, infection fatality risk estimation requires infection data from a large-scale seroepidemiological survey combined with either direct ascertainment of deaths caused by infection or excess mortality estimates. To overcome the difficulty in ascertaining death, we propose an alternative approach to estimating the age-specific infection fatality risk for SARS-CoV-2 using medicolegal death investigation data in Tokyo with systematic post-mortem polymerase chain reaction testing. We integrated (i) polymerase chain reaction positivity among all deceased individuals at the Tokyo Medical Examiner’s Office, (ii) age-specific all-cause mortality risks from vital statistics, and (iii) age-stratified cumulative infection risks derived from seroepidemiological surveys. Infection fatality risk was computed using Bayes’ theorem. Results showed that infection fatality risk increased steeply with age. Our estimates (0.02% for ages 0–39 years, 0.30%–0.50% for ages 40–64 years, and 3.8%–4.2% for those aged ≥65 years) were consistent with published pre-vaccination meta-analytic estimates. Systematic testing within medicolegal death investigation systems can provide rapid, age-resolved severity assessments, improving the timeliness and comparability of infection fatality risk estimation across jurisdictions. Introduction The infection fatality risk (IFR), defined as the probability of death among all infected individuals, is an essential metric for quantifying clinical severity and comparing virulence across pathogens, settings, and time [1, 2]. During the influenza-A/H1N1 pandemic, age-specific IFR estimates were used to characterize severity gradients by age and address ascertainment biases in mortality outcome assessment [3]. IFR estimation was crucial for public health decision-making during the COVID-19 pandemic, playing a central role in interpreting infection severity, identifying high-risk populations (e.g., older adults), modelling epidemic trajectories (e.g., in the absence of interventions), and predicting overall mortality [4, 5]. Statistical estimation of the IFR has traditionally been performed by coupling observed death counts with independently estimated cumulative infections, typically inferred from population-based seroepidemiological surveys [2, 4, 6–10]. To translate seroepidemiological datasets into cumulative infection risk, various studies have proposed methods to account for and address imperfect testing performance, employing hierarchical Bayesian measurement-error frameworks that propagate uncertainty in sensitivity and specificity [11, 12]. Additionally, because antibody waning and seroreversion following an infection can cause fluctuations in seropositivity, recent research has suggested incorporating time-varying sensitivity and antibody kinetics into models to improve the estimation of cumulative incidence from sequential serosurvey data [13]. However, the vast majority of seroepidemiological surveys are still resource-intensive to implement and sustain, and non-random participation in blood collection remains a concern. Recruitment and non-response biases can link participation to infection risk, symptom history, and risk perception, thereby distorting the denominator of the IFR [14–17]. Furthermore, the death count may be affected by surveillance processes, especially for mild infectious diseases. In many settings, routine reporting and vital registration systems cannot capture all deaths attributable to an infectious disease. Consequently, excess-mortality estimation has been employed as an alternative, often producing a value that exceeds the ascertained number of deaths, and the accurate excess mortality estimate may provide a lower bound of COVID-19 deaths [18, 19]. Bias and uncertainty in both the numerator (deaths) and the denominator (infected) of the IFR are recognized as influential problems, and unbiased IFR estimation remains a challenge for public health practice. Developing multiple complementary approaches to IFR estimation could improve its robustness and enhance its resilience to method-specific biases and limitations. A valuable yet underused source of data is the medicolegal death investigation system, which includes forensic autopsy programmes that utilize systematic post-mortem testing and standardized cause-of-death assessment. Death investigations can determine infection status among decedents via routine cause-of-death surveillance, thereby estimating the number of individuals infected with COVID-19. The autopsy system in Tokyo’s metropolitan areas operates across all 23 special wards, where all medicolegal deaths, including those with natural, non-natural, and undetermined causes, are reported to the Tokyo Medical Examiner’s Office. Between 2020 and 2021, medicolegal investigations of abnormal deaths in these wards included reverse transcription-polymerase chain reaction (RT-PCR) testing for COVID-19, post-mortem computed tomography, and administrative autopsy [20]. Previous studies have used autopsy data to evaluate the causal relationship between death and SARS-CoV-2 positivity, as well as to investigate mortality following COVID-19 vaccination [21, 22]. Rather than focusing on causality, the present study exploits these data to reflect population-level COVID-19 risk. The objective of this research was to estimate age-specific IFRs for COVID-19 using medicolegal death investigation data, including forensic autopsy RT-PCR results, obtained from the Tokyo Medical Examiner system across the 23 special wards of Tokyo. We also performed a sample size calculation to determine the minimum number of autopsies requiring RT-PCR testing under a fixed IFR assumption. Methods Epidemiological autopsy and seroprevalence data We used three independent empirical datasets to estimate the age-dependent IFR of SARS-CoV-2. First, we obtained autopsy data from the Tokyo Medical Examiner’s Office, which had conducted systematic medicolegal death investigations in the 23 special wards of Tokyo from March 2020 to February 2021 [20]. The dataset included the count of positive cases as determined by post-mortem nasopharyngeal RT-PCR testing, stratified into three age groups (≤39 years, 40–64 years, and ≥65 years). We also used the cumulative number of autopsies conducted at the Tokyo Medical Examiner’s Office [23]. Second, we derived the cumulative incidence of SARS-CoV-2 infection in the Tokyo Metropolitan Area from two independent seroepidemiological surveys that collected residual clinical specimens using a chemiluminescence immunoassay [24] and an enzyme-linked immunosorbent assay (ELISA) [25] to detect IgG antibodies against the SARS-CoV-2 nucleocapsid (N) and spike (S) proteins. The incidence of infection was estimated from a cross-sectional survey of leftover serum at 14 Tokyo outpatient clinics between 1 September 2020 and 31 March 2021, restricted to patients without a prior COVID-19 diagnosis or symptoms at the time of blood collection [24]. We also examined data from another study of residual serum or plasma collected for medical examination from patients visiting healthcare facilities in the Tokyo Metropolitan Area between February 2020 and March 2022, which again excluded patients with positive SARS-CoV-2 nucleic acid or antigen tests [25]. Third, we used vital statistics to extract age-specific numbers of all-cause deaths and mid-year population sizes for the abovementioned study period and region [26, 27]. Estimation of age-specific IFR We estimated age-specific IFR by applying Bayes’ theorem to combine serologically inferred cumulative risk of infection with medicolegal death investigation data quantifying SARS-CoV-2 infection risk among autopsied dead individuals. Let the age-specific IFR for the age group aa be IFRa=PrAa∣BaIFRa equals PrAa vertical bar Ba , where Aupper A represents death from all causes and Bupper B denotes SARS-CoV-2 infection. It should be noted that our IFR is thus regarded as the conditional risk of death given infection and that here it does not handle the causal risk of death. Using Bayes’ theorem, the age-specific IFRaIFRa was rearranged as (1) PrAaBa=PBaAaPAaPBa,PrAaBa equals PBaAaPAaPBa comma where specific to age group aa , PBa∣AaPBa vertical bar Aa denotes the probability that a decedent was infected with SARS-CoV-2, PAaPAa denotes the probability of death during the study period, and PBaPBa denotes the cumulative risk of infection with SARS-CoV-2. Empirically, the conditional probability PBa∣AaPBa vertical bar Aa can be estimated using the age-specific risk of SARS-CoV-2 infection among decedents in the 23 special wards of Tokyo between March 2020 and February 2021. To account for limited sensitivity, we computed the true positivity proportion using the Rogan–Gladen estimator [28] and the Bayesian estimation model. The details of the procedure are provided in the Supplementary Material. The infected proportion of the population PBaPBa was obtained from age-stratified seroepidemiological data, adjusted for assay sensitivity and specificity using the Rogan–Gladen estimator [28]. Let yaseroyasero and naseronasero denote the number of seropositive individuals and the number tested in age group aa , respectively, with an observed seropositivity proportion of pa,obssero=yasero/naseropa comma obssero equals yasero slash nasero . The adjusted seroprevalence was calculated as (2) πasero=pa,obssero+spsero−1sesero+spsero−1.pi asero equals pa comma obssero plus spsero minus 1 sesero plus spsero minus 1 period In addition to RT-PCR testing, we calculated the true positivity of the assay using the Rogan–Gladen estimator. We assigned study-specific values for serological assay sensitivity and specificity. Specifically, for Sanada et al.’s study [24], we used sesero=0.636sesero equals 0.636 and spsero=1.0spsero equals 1.0 , whereas for Yamayoshi et al.’s study [25], we used sesero=0.995sesero equals 0.995 and spsero=1.0spsero equals 1.0 . Because the seroepidemiological surveys spanned a finite sampling period, we rescaled the infection risk using a scaling factor ra=La/Tra equals La slash upper T , where LaLa is the age-group specific mean time from the onset of COVID-19 symptoms to death, which was computed from individual death records from 2020 [29], and T is the duration of the sero-survey sampling period. The rescaled risk of infection was defined as PBa=πaseroraPBa equals pi aserora . Combining these data with Equation (1), we calculated age-specific IFR and quantified the uncertainty in these estimates. To quantify uncertainty in the age-specific IFR estimates, we used a parametric bootstrap method; detailed descriptions are available in the Supplementary Material. We compared our age-specific IFRs with values published in systematic reviews and meta-analyses [2, 4, 30–35], as well as with published country-specific IFR estimates from the pre-vaccination era [2, 5, 33, 36, 37]. Relationship between IFR and RT-PCR positivity during autopsies To facilitate the prediction of a fixed IFR value from the empirically observed proportion of RT-PCR positives among autopsied individuals, we examined the relationship between (i) the estimated cumulative risk of infection derived from sero-surveys and (ii) all-cause mortality. We adjusted for test performance by setting the sensitivity and specificity of the sero-survey to seser=0.805seser equals 0.805 and spser=1.0spser equals 1.0 , and those of RT-PCR performance to sePCR=0.733sePCR equals 0.733 and spPCR=0.999spPCR equals 0.999 [38–40]. The sensitivity of RT-PCR was based on pooled estimates from a meta-analysis [39], which synthesized evidence from four studies evaluating the sensitivity of RT-PCR testing of nasopharyngeal aspirates, nasopharyngeal swabs, and throat swabs in symptomatic patients. Supposing that the all-cause mortality risk of PAPA was that of vital statistics for 2020 and ra=24/180ra equals 24 slash 180 , where 24 days represents the mean duration from COVID-19 symptom onset to death, and 180 denotes the duration of a sero-survey sampling period. Using seroprevalence, a fixed IFR value, and Equation (1), we first derived the true PCR positivity from rara , PAaPAa , and πseropi sero . We then incorporated the sensitivity and specificity of RT-PCR to derive the expected RT-PCR positivity proportion via the Rogan–Gladen estimator. Required sample size for autopsy We performed a sample size calculation to determine the number of deceased individuals required for autopsy and RT-PCR testing to estimate the IFR within several predefined error levels. The calculation is based on the expected RT-PCR positivity among decedents, denoted by πopi o . Because the IFR is close to zero, the required sample size was derived using the Wilson score confidence interval for a binomial proportion. This approach is preferred over the Wald method because of its superior reliability [41]. Let 1−α1 minus alpha be the confidence level and z1−α/2z 1 minus alpha slash 2 the corresponding standard normal quantile. For a target absolute margin of error εepsilon on πopi o , the required sample size Nupper N is (3) N=Z1−α/22πo1−πo−2ε2+πo21−πo2+4ε2πo−1222ε2.upper N equals upper Z 1 minus alpha slash 22 pi o 1 minus pi o minus 2 epsilon 2 plus pi o 21 minus pi o 2 plus 4 epsilon 2 pi o minus 1222 epsilon 2 period Details of errors in the translation from RT-PCR positivity to the IFR are provided in the Supplementary Material. Assuming that specific seroprevalence data (e.g., anti-nucleocapsid antibody) are not influenced by vaccine-induced immunity, we computed the required sample sizes for three margins of error for the IFR, defined by relative errors of 5%, 10%, and 20%. Ethical considerations The present study used only publicly available data that had been anonymized by the data source institutes. No personally identifiable information was accessed or handled. Results A total of 14574 autopsies were carried out between 1 March 2020 and 28 February 2021. Of these, 60 cases tested positive for SARS-CoV-2, yielding a positivity rate of 0.41%. The estimated age-specific RT-PCR positivity was 0.25% (95% credible interval (CI) 0.01–0.91) among individuals aged ≤39 years, 0.40% (95% CI 0.02–0.97) for those aged 40–64 years, and 0.28% (95% CI 0.01–0.59) for those aged ≥65 years. The estimated IFR was 0.02% (95% CI 0.0007–0.06) for 0–39 years, 0.30% (95% CI 0.01–0.59) for 40–64 years, and 3.8% (95% CI 0.20–8.79) for those aged 65 years and older, using seroprevalence data from Sanada et al. [24]. Using the seroprevalence data from Yamayoshi et al.’s study [25], the estimated IFR for the three age groups was 0.02% (95% CI 0.0011–0.10), 0.50% (95% CI 0.03–1.44), and 4.22% (95% CI 0.19–10.4), respectively. Figure 1 shows the IFR estimated using each sero-survey dataset, compared against published estimates of IFR during the pre-vaccination period. The IFR increased exponentially with age.Figure 1.Estimated age-specific infection fatality risk of COVID-19 compared with published estimates during the pre-vaccination period.The horizontal axis shows age in years, and the vertical axis shows infection fatality risk (IFR) on a logarithmic scale. Study-specific point estimates are distinguished by colour and symbol: Estimates from Sanada et al. [24] are shown as red circles, and those from Yamayoshi et al. [25] are shown as orange diamonds, each with a vertical 95% interval. Published estimates are represented by purple inverted triangles for O’Driscoll et al. [4], brown triangles for Pezzullo et al. [31], blue squares for Brazeau et al. [30], green plus symbols for Levin et al. [2], pink asterisks for the COVID-19 Forecasting Team [32], light-blue crosses for Levin et al. [33], coral-coloured filled circles for Herrera-Esposito and de los Campos [35], and yellow filled diamonds for Axfors and Ioannidis [34].Scatter plot of infection fatality risk. The horizontal axis shows age and The vertical axis shows infection fatality risk on a log y-axis, comparing ten studies’ estimates. Across all sources, IFR rises steeply and roughly log-linearly with age. Estimated age-specific infection fatality risk of COVID-19 compared with published estimates during the pre-vaccination period. The horizontal axis shows age in years, and the vertical axis shows infection fatality risk (IFR) on a logarithmic scale. Study-specific point estimates are distinguished by colour and symbol: Estimates from Sanada et al. [24] are shown as red circles, and those from Yamayoshi et al. [25] are shown as orange diamonds, each with a vertical 95% interval. Published estimates are represented by purple inverted triangles for O’Driscoll et al. [4], brown triangles for Pezzullo et al. [31], blue squares for Brazeau et al. [30], green plus symbols for Levin et al. [2], pink asterisks for the COVID-19 Forecasting Team [32], light-blue crosses for Levin et al. [33], coral-coloured filled circles for Herrera-Esposito and de los Campos [35], and yellow filled diamonds for Axfors and Ioannidis [34]. Figure 2 provides an age-stratified comparison between our IFR estimates and published estimates. Across all age groups, our estimated IFR generally fell within the ranges reported internationally for comparable periods. Among people aged from 0 to 39 years, IFR values were consistently very small, as reported elsewhere [2]. Among those aged between 40 and 64 years, our IFR estimate was close to those reported in European settings (e.g., Belgium 0.02%; 95% CI 0.02–0.03) but substantially smaller than those reported in North America and parts of Europe. Among those 65 years and older, estimated IFR values were consistent with other estimates from Japan.Figure 2.Forest plot of infection fatality risk estimates by study and age group.Each row corresponds to one study. Results are shown for up to three age groups: 0–39 years, 40–64 years, and ≥ 65 years. Each row displays study location, age group, study period, and IFR estimates as points with horizontal 95% confidence intervals. The exact estimate with its 95% interval is printed to the right of the plot.Forest plot of infection fatality risk by age (0-39, 40-64, 65+). Compares Asian and non-Asian populations; results are consistent with previous studies. Forest plot of infection fatality risk estimates by study and age group. Each row corresponds to one study. Results are shown for up to three age groups: 0–39 years, 40–64 years, and ≥ 65 years. Each row displays study location, age group, study period, and IFR estimates as points with horizontal 95% confidence intervals. The exact estimate with its 95% interval is printed to the right of the plot. Figure 3 depicts the modelled interdependent relationships among IFR, seroprevalence, and expected RT-PCR positivity at autopsy. The expected RT-PCR positivity is positively associated with both IFR and seroprevalence. Conversely, the contours illustrate the trade-off between IFR and seroprevalence. For a given RT-PCR positivity rate, a high IFR value indicates a small seroprevalence (and vice versa).Figure 3.Relationship between IFR and RT-PCR positivity during autopsies.The horizontal axis shows the infection fatality risk (IFR), and the vertical axis shows the proportion of the population infected. The heatmap indicates the expected proportion of RT-PCR positivity at autopsy, with darker shading representing higher positivity, as shown in the colour bar. White contour lines show equal values of expected RT-PCR positivity across the heat map.Heat map on the relationship between IFR and RT-PCR positivity. The horizontal axis shows the IFR, and the vertical axis shows the proportion of the population infected. Autopsy RT-PCR positivity tended to increase with proportion infected and IFR. Relationship between IFR and RT-PCR positivity during autopsies. The horizontal axis shows the infection fatality risk (IFR), and the vertical axis shows the proportion of the population infected. The heatmap indicates the expected proportion of RT-PCR positivity at autopsy, with darker shading representing higher positivity, as shown in the colour bar. White contour lines show equal values of expected RT-PCR positivity across the heat map. Figure 4 shows the required autopsy sample size, defined as the number of autopsies needed to estimate the IFR within prespecified relative errors of 5%, 10%, and 20%. The results indicate an inverse relationship between the expected IFR and the required sample size. As the IFR decreases, the sample size necessary to achieve the same relative precision increases rapidly, becoming very large. For any given IFR, a tighter relative error requires a substantially larger sample size than a wider error margin. For example, when the IFR is 1%, the sample sizes required to achieve relative errors of 5%, 10%, and 20% are 21673, 5556, and 1474, respectively.Figure 4.Required number of deceased individuals for autopsy and RT-PCR testing to estimate the IFR within predefined relative error levels.The horizontal axis represents the infection fatality risk on a logarithmic scale. The vertical axis represents the required number of deceased individuals for RT-PCR testing. The curves correspond to relative error margins of 5%, 10%, and 20% for the IFR estimate, shown in purple, green, and yellow, respectively.Line plot of required sample size for estimating the IFR. The horizontal axis represents IFR and the vertical axis represents the required number of deceased individuals for RT-PCR testing. As the IFR decreases, the required sample size increases. Required number of deceased individuals for autopsy and RT-PCR testing to estimate the IFR within predefined relative error levels. The horizontal axis represents the infection fatality risk on a logarithmic scale. The vertical axis represents the required number of deceased individuals for RT-PCR testing. The curves correspond to relative error margins of 5%, 10%, and 20% for the IFR estimate, shown in purple, green, and yellow, respectively. Discussion RT-PCR testing for SARS-CoV-2 was routinely carried out at the Tokyo Medical Examiner’s Office from 2020 to 2021. We combined these testing results with seroepidemiological data and the total all-cause death count to estimate the age-specific IFR for COVID-19 in Tokyo. The estimated age-specific IFRs increased steeply with age and were consistent with published estimates from meta-analyses and country-specific studies during the pre-vaccination period. We also characterized the relationships among IFR, seroprevalence, and expected RT-PCR positivity at autopsy and quantified the required autopsy sample size for several prespecified levels of relative error. This proposed estimation method can serve as a practical alternative approach to the conventional IFR estimation procedure (i.e., dividing observed or estimated deaths by the serologically estimated cumulative incidence of infection). Our findings highlight the practical value of medicolegal death investigation data in assessing the severity of an emerging infectious disease. By introducing post-mortem infection data into the public health evaluation framework, we have demonstrated that the IFR can be double-checked against a conventional estimate derived from the number of COVID-19 deaths and the seroepidemiologically estimated infection size [8]. The direct estimation method struggles to accurately ascertain deaths, requiring either direct counting of causally evident deaths (e.g., deaths due to viral pneumonia) or indirect estimates (e.g., derived from the excess mortality estimation method). Both conventional methods and our proposed approach require seroepidemiological estimates of infection incidence. However, our method overcame the challenges of attributing deaths causally. In particular, when infection (e.g., influenza or COVID-19) makes it impossible to fully ascertain the cause of death, our alternative approach can help ensure the validity of the IFR estimate. While the proposed method produced reasonable IFR estimates, and the age-specific IFR values were consistent with published data, indicating that COVID-19 severity in Asia, including Japan, was not intrinsically lower than in other regions [42, 43], it is vital to discuss the potential pitfalls of this approach. That is, it is essential to consider that medicolegal death investigations handle deaths following acute exacerbations and accidents; therefore, potential selection bias could yield erroneous IFR estimates. For instance, if an autopsy dataset of acute deaths included a substantial number caused by acute myocardial infarction (a known complication of COVID-19) [44], the observed RT-PCR positivity of the sample may be greater than that of the entire population of deceased individuals, including those not autopsied. While the Tokyo Medical Examiner’s Office routinely tests deceased individuals, reducing this potential bias, the most promising remedy is to screen all deaths for SARS-CoV-2 regardless of autopsy. In addition to measuring the overall severity of an emerging disease, the IFR is useful for assessing the probability of death among high-risk individuals (e.g., those with underlying comorbidities). Computing the age-specific IFR was not technically challenging because we were able to derive PAaPAa in Equation (1), the risk of death in age group a, directly from vital statistics. Measuring the IFR PrAi∣BiPrAi vertical bar Bi among those with comorbidity i is far more difficult. That is, the risk of death PAiPAi among individuals with comorbidity i is required, and the seroprevalence estimate PBiPBi must also be stratified by comorbidity. Routinely recording underlying comorbidities on death certificates and through seroepidemiological surveys is therefore crucial, and the underlying population-level estimate of individuals with disease i should be regularly updated. To improve pandemic preparedness, our proposed technique should be incorporated into the global public health infrastructure by systematically screening decedents to enable the use of the dataset for epidemiological purposes. Our sample size calculations indicate that even when the IFR is approximately 1%–2%, achieving tight relative precision can require tens of thousands of RT-PCR tests at autopsy. This suggests that no single jurisdiction is likely to accumulate sufficient observations rapidly during an initial wave. Accordingly, an effective strategy would combine routine pathogen testing of deceased individuals undergoing medicolegal investigation with standardized data elements and a mechanism for timely linkage and pooled aggregation across jurisdictions. Considering additional needs for datasets stratified by age and underlying comorbidities, integrating electronic health record data (e.g., to provide prevalence estimates of underlying comorbidities) and digital transformation technologies (e.g., automated identification of high-risk groups) may be key to future success, as well as to establishing an analytic pipeline for IFR computation. Furthermore, as a published study explored seroprevalence with post-mortem PCR analysis to estimate the IFR [45], our sample size calculation will be valuable for planning similar epidemiological studies. By examining the relationship between IFR and RT-PCR positivity at autopsy, our study demonstrated that RT-PCR testing implemented within medicolegal autopsy practice can facilitate the use of observed positivity to infer a plausible range of IFR values under fixed assumptions about seroprevalence and all-cause mortality risk. This relationship is particularly useful during the early stage of a pandemic, when uncertainty about infection incidence and incomplete case ascertainment complicate direct IFR estimation. Four limitations of the proposed approach should be discussed. First, while the sensitivity of RT-PCR and serological assays for SARS-CoV-2 is known to vary with time since infection [46, 47], we treated RT-PCR sensitivity as fixed because data on infection timing were unavailable. Although anti-nucleocapsid (N) antibodies are known to wane rapidly, the two surveys we referenced also incorporated spike (S) protein targets, which have been shown to maintain high sensitivity and persistent detection over time [47]. Additionally, routine RT-PCR testing is expensive, whereas antigen testing could enable the assessment of a larger number of deceased individuals at a lower cost. Furthermore, antigen testing may not be essential when recent infection can be reasonably inferred from serological markers, such as IgM antibodies. Second, our death numerator relies on post-mortem RT-PCR, which detects SARS-CoV-2 RNA only when viral material remains present at the time of autopsy. This misclassification results in an underestimation of our estimated IFR. Third, our medicolegal data were collected from a single metropolitan area, which may limit the generalizability of the findings to settings with different demographic structures, healthcare access, epidemic timing, and medicolegal investigation practices. Seroepidemiological surveys employing a random sampling method in Japan were carried out across different survey periods and geographic regions and have reported different seroprevalence estimates compared with Sanada et al. and Yamayoshi et al. [24, 25, 48, 49]. Fourth, although the age-specific cumulative risk of infection was derived from a seroepidemiological survey, the present framework could not account for selection bias arising from the participant inclusion process in seroepidemiological studies [17]. In conclusion, we estimated age-specific IFR using forensic autopsy data, and the findings highlight the practical value of medicolegal death investigation for severity assessment during an emerging pandemic. The proposed alternative approach to estimating IFR helps overcome uncertainties arising from technical difficulty in the conventional method, including ascertainment of the cause of death. Supporting information Amemiya and Nishiura supplementary material Amemiya and Nishiura supplementary material